REPL vs UNH

Replimune (REPL) maintains a high-conviction, high-risk, high-reward profile, with its score slightly increasing due to recent positive developments. The previous analysis heavily anticipated pivotal RP1 data, and an update from the Phase 3 IGNYTE trial in anti-PD1 failed melanoma patients showing a 32% ORR (Mar 22, 2026) provides strong preliminary validation. This significantly de-risks the prim...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...